Icahn School of Medicine at Mount Sinai
New York, 10029, United States
Location contact
Carlos G Santos-Gallego
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07572175
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 2
New York, 10029, United States
Carlos G Santos-Gallego
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sotagliflozin 400mg starting prior to the first scheduled anthracycline infusion
Placebo starting prior to the first scheduled anthracycline infusion
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
LVEF is a measure of contractility of the heart (strength of contraction). Normal values are between 55-65%. It is the most widely used parameter by physicians worldwide to measure cardiac contractility.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
Longitudinal strain is the deformation of a material per unit length, defined as the ratio of change in length to the original length in the direction of an applied load. It measures how much an object stretches (tensile) or compresses (compressive) along its axis Longitudinal strain is an echocardiographic technique that quantifies the percentage of systolic shortening of the heart muscle from base to apex. It is a highly sensitive indicator of left ventricular function, detecting subclinical, early myocardial dysfunction (e.g., in cardio-oncology) often before the ejection fraction (LVEF) drops. Normal GLS values are typically >18%.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
LVEF is a measure of contractility of the heart (strength of contraction). Normal values are between 55-65%. It is the most widely used parameter by physicians worldwide to measure cardiac contractility.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
LV volumes measure how enlarged the heart is. Chemotherapy destroys cardiac muscle and enlarges the heart (ie. increases LV volumes). The higher the LV volumes, the more damage by chemotherapy.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
LV mass measures the amount of cardiac muscle. Chemotherapy destroys cardiac muscle. The lower the LV mass, the more damage by chemotherapy.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
Longitudinal strain is the deformation of a material per unit length, defined as the ratio of change in length to the original length in the direction of an applied load. It measures how much an object stretches (tensile) or compresses (compressive) along its axis Longitudinal strain is an echocardiographic technique that quantifies the percentage of systolic shortening of the heart muscle from base to apex. It is a highly sensitive indicator of left ventricular function, detecting subclinical, early myocardial dysfunction (e.g., in cardio-oncology) often before the ejection fraction (LVEF) drops. Normal GLS values are typically >18%.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
The 6MWT assesses endurance and ability to walk over longer distances. The 6MWT was first described as a field test for physical fitness in 1963 and then as a 12-minute walk test in people with chronic bronchitis. The 6MWT was found to perform as well as the 12-minute walk, and is now used to assess the submaximal level of functional performance at a similar level required for daily physical activities.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
NT-ProBNP is a plasma biomarker of cardiac stress, cardiac tension and severity of heart failure. The higher the NT-ProBNP level, the more severe the heart failure induced by chemotherapy.
Time frame: Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.
Troponin I is a plasma biomarker of cardiac injury and cardiac damage. The higher the troponin levels, the more cardiac damage induced by chemotherapy.
Contact information is provided by the study sponsor or research team.
Carlos G Santos-Gallego, MD
CONTACT
Juan Antonio Requena-Ibanez
CONTACT
Icahn School of Medicine at Mount Sinai
Other
SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)
Acronym: SPARTACUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07528586
Anthracycline-induced Cardiotoxicity, Cardiotoxicity
Stuttgart, Germany
View Trial DetailsNCT07442578
Anthracycline-induced Cardiotoxicity, Cardiotoxicity
Boston, Massachusetts, United States
View Trial DetailsNCT07254221
Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiac Toxicity
Shiraz, Fars, Iran
View Trial DetailsNCT01805778
Anthracycline-induced Cardiotoxicity
Orange, California, United States
View Trial Details